GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (NAS:MYGN) » Definitions » Shiller PE Ratio
中文

Myriad Genetics (Myriad Genetics) Shiller PE Ratio

: (As of Today)
View and export this data going back to 1995. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Myriad Genetics Shiller PE Ratio Historical Data

The historical data trend for Myriad Genetics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.44 11.49 37.54 31.94 -

Myriad Genetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.94 69.27 181.43 - -

Competitive Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Shiller PE Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Shiller PE Ratio falls into.



Myriad Genetics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Myriad Genetics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Myriad Genetics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.36/129.4194*129.4194
=-0.360

Current CPI (Dec. 2023) = 129.4194.

Myriad Genetics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.480 99.695 0.623
201406 0.430 100.560 0.553
201409 0.210 100.428 0.271
201412 0.320 99.070 0.418
201503 0.290 99.621 0.377
201506 0.260 100.684 0.334
201509 0.420 100.392 0.541
201512 0.500 99.792 0.648
201603 0.470 100.470 0.605
201606 0.320 101.688 0.407
201609 -0.020 101.861 -0.025
201612 0.090 101.863 0.114
201703 0.060 102.862 0.075
201706 0.190 103.349 0.238
201709 1.120 104.136 1.392
201712 0.430 104.011 0.535
201803 0.130 105.290 0.160
201806 0.180 106.317 0.219
201809 -0.010 106.507 -0.012
201812 0.030 105.998 0.037
201903 0.090 107.251 0.109
201906 -0.060 108.070 -0.072
201909 -0.280 108.329 -0.335
201912 -0.110 108.420 -0.131
202003 -1.550 108.902 -1.842
202006 -0.740 108.767 -0.881
202009 -0.200 109.815 -0.236
202012 -0.510 109.897 -0.601
202103 -0.520 111.754 -0.602
202106 -0.060 114.631 -0.068
202109 0.300 115.734 0.335
202112 -0.100 117.630 -0.110
202203 -0.260 121.301 -0.277
202206 -0.180 125.017 -0.186
202209 -0.430 125.227 -0.444
202212 -0.520 125.222 -0.537
202303 -0.670 127.348 -0.681
202306 -1.420 128.729 -1.428
202309 -0.750 129.860 -0.747
202312 -0.360 129.419 -0.360

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Myriad Genetics  (NAS:MYGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Myriad Genetics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics (Myriad Genetics) Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
Executives
Richard Bryan Riggsbee officer: Chief Financial Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Heinrich Dreismann director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Nicole Lambert officer: Chief Operating Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Margaret Ancona officer: SVP, Chief of Staff 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Pamela Wong officer: Chief Legal Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Shereen Solaiman officer: Chief People Officer 320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Bisaro director
Dale Muzzey officer: Chief Scientific Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Kevin Richard Haas officer: Chief Technology Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Natalie Munk officer: Chief Accounting Officer 322 NORTH 2200 WEST, SALT LAKE CITY UT 84116
Lee Nisley Newcomer director 264 BUSHAWAY ROAD, WAYZATA MN 55391-1901
Rashmi Kumar director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jayne B. Hart officer: Executive VP Human Resources 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jerry S Lanchbury officer: Senior V.P. - Research 320 WAKARA WAY, SALT LAKE CITY UT 84108